CRSP

CRISPR Therapeutics AG (CRSP) | Rumor.io

CRISPR Therapeutics

CRSP

Attention (50-day avg)0.01%

Attention rank (50-day avg)#521

Bullish sentiment (50-day avg)91%

Price to earnings ratio-8.36

Market capitalization5.2B

Earnings per share-4.71

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-581.6M

Social

What share of all stock conversation is about CRSP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.01% 0	0.01% 0	0.02% -0.01

Sep 23

$CRSP has been trading in a narrow range for a while, with $60 acting as a resistance level; it's unclear when it will break through and what will happen next.
The recent discovery by Anthropic's biolab, comparing its results to CRISPR, is not a present threat to CRISPR Therapeutics; Anthropic's AI is still in its early stages, and gene editing companies like CRISPR already have proprietary technology.
CRISPR Therapeutics' stock could see a significant increase if the company lands a major partnership for its CTX310 drug, which is expected to happen soon given the positive phase 1b data; this would likely dwarf the market's attention to other biotech companies.

Generated by AI

Sentiment

Of the messages about CRSP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	91.25% -4.8	93.42% +3.78	82.59% +2.96
Bearish	0% 0	8.75% +4.8	6.58% -3.78	17.41% -2.96

Bullish· Aug 19

$CRSP has the potential to break out of its long consolidation and make a significant move, with some analysts predicting a price explosion to $85-$115 per share.
The company's gene editing technology, approved by Casgevy, has the potential to revolutionize medicine, making it a leader in the sector and a key player in the future of healthcare.
$CRSP's pipeline is expanding rapidly, with a total addressable market (TAM) of $50B-$100B, making it a prime target for investors looking for a long-term gem in the biotech sector.

Bearish· Jun 4

The stock has been sold by some investors, with one user mentioning a sale at $58 and another warning not to follow Cathy's advice to sell.
The company's valuation is being questioned, with one user suggesting that it is overvalued compared to space companies, and another implying that it is undervalued and forgotten.
The stock's price has been experiencing volatility, with users mentioning a drop below $57, a failed attempt to close above $57, and a potential sell-off in the future.

Generated by AI

Topics

Of the messages about CRSP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	60%	11.54%	22.48%	48.74%
Announcements	40%	13.85%	40.19%	2.02%
Analysts	0%	37.31%	18.86%	48.32%
Earnings	0%	0%	0%	0.02%
Macro	0%	37.31%	18.48%	0.84%
Controversies	0%	0%	0%	0.06%

Earnings· Feb 21

CRISPR Therapeutics AG's Q4 EPS was $1.10, beating the estimate by $1.51.
Sales for Q4 were $201.21M, exceeding the estimate of $131.63M.
The company's revenue topped estimates by $70.98M, with a year-over-year increase of 3253.3%.

Analysts· Dec 11

Analysts have raised their price targets for CRISPR Therapeutics AG (CRSP) to $57-$88, citing the FDA approval of its gene therapy Casvegy.
Needham and Company LLC raised its price target to $88, while JMP Securities raised its target to $80, and Barclays increased its target to $61.
Truist analysts downgraded their price target to $160 from $220, citing scaled-back optimism for Casvegy deployment, while TD Cowen downgraded CRSP to Underperform with a $30 price target.

Announcements· Mar 11

CRISPR Therapeutics AG has priced an upsized convertible senior notes offering of $550M, with a maturity date of March 1, 2031, and an option to purchase an additional $50M.
The offering was upsized from the initially announced $350M, with the proceeds expected to be used for general corporate purposes.
The notes will have an effective coupon of 1.7308%, with interest payable semiannually in arrears, and will be senior, unsecured obligations of the company.

Controversies· Jun 11

CRISPR Therapeutics AG's gene-editing technology may cause cancer, according to two studies, leading to a decline in stock prices for CRSP and similar companies.
The CEO of CRSP, Sam Kulkarni, acknowledged the potential cancer threat, stating that the results of the studies were "plausible".
Gene-editing startups, including CRSP and Editas Medicine, downplayed the potential cancer side effect, with some studies suggesting that the technology may not be as risky as initially thought.

Technical Analysis· Dec 11

$CRSP is holding back testing and down-trend line, with an ideal scenario being an undercut and rally.
$CRSP's pullback after a massive run is considered normal action, following a wave 2 pattern, and is expected to bounce back up.
$CRSP's daily chart is forming a bear flag, and it is expected to see a bounce off the 200-day moving average, potentially at $52 or $53.

Generated by AI

Community

Of the messages about CRSP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	51.35%	32.09%	46.77%	18.91%
Newcomers	48.65%	67.91%	53.23%	81.09%

Regulars· Sep 23

$CRSP's stock price is stuck in a tight range, and regulars are waiting to see when it will break through and what will happen next.
Anthropic's discovery is being compared to CRISPR's, but regulars believe that Anthropic's biotech arm is a long way off, and they will need to build a lot of bench work and context to truly have a functional biotech arm.
The market is delusional about AI's potential to fast-track clinical trials, and regulars believe that CRISPR's stock will continue to be driven by the company's pipeline and potential partnerships, which could send the stock to 100+ in a heartbeat.

Newcomers· Jun 18

New investors are entering the market, as evidenced by the comment "dammit just bought CRSP", indicating a recent purchase of the asset.
Some newcomers are expressing frustration or excitement about their investment, as seen in the comment "dammit", suggesting a strong emotional response to the asset's performance.
The asset is being bought, rather than sold, indicating a bullish sentiment among these newcomers.

Generated by AI

News

CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?

1d agoYahoo Finance

CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens

2d agoInvesting.com

CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality

4d agoInvesting.com

CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As Book Value Questions Linger

5d agoYahoo Finance

Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP)

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's success and management’s execution in ex vivo gene editing. Click for more on CRSP.

5d agoSeeking Alpha

Gene editing stocks fall on Anthropic’s CRISPR-like discovery

Gene editing stocks fall as Anthropic’s (ANTHRO) AI model Claude discovers a new enzyme system similar to the gene-editing tool CRISPR. Read more here.

6d agoSeeking Alpha

Also Discussed

Investors talking about CRSP also mention

#	Name	Attention
1	Intellia Therapeutics, Inc.NTLA	0%+0
2	Editas Medicine, Inc.EDIT	0%+0
3	Beam Therapeutics IncBEAM	0.02%+0.02
4	Caribou Biosciences, Inc.CRBU	0%0
5	Vertex Pharmaceuticals Incorporated Common StockVRTX	0%-0.01
6	ARK Genomic Revolution ETFARKG	0.25%+0.09
7	Prime Medicine, Inc.PRME	0%-0.01
8	Pacific Biosciences of California, Inc. Common StockPACB	0%0
9	Twist Bioscience CorporationTWST	0%-0.02
10	SGMO - Sangamo Therapeutics, Inc.	——

CRISPR Therapeutics AG

Healthcare
Biotechnology

CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing and the development of CRISPR/Cas9-based medicines for serious human diseases. Its research and therapeutic portfolio spans areas such as hemoglobinopathies, oncology, regenerative medicine, autoimmune disorders, and type 1 diabetes. The company’s work centers on using precise genome editing to create targeted cell and gene therapies, with a particular emphasis on advancing treatments derived from its proprietary CRISPR platform. CRISPR Therapeutics AG also collaborates with partners in the life sciences sector to develop and commercialize selected programs, strengthening its role in the broader healthcare innovation landscape. Headquartered in Zug, Switzerland, the company is a notable participant in the biotechnology market, where it contributes to the growing field of gene-based medicine.

Website

Location

Baarerstrasse 14

Zug, 6300

Switzerland

Social

What share of all stock conversation is about CRSP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.01% 0	0.01% 0	0.02% -0.01

Sep 23

$CRSP has been trading in a narrow range for a while, with $60 acting as a resistance level; it's unclear when it will break through and what will happen next.
The recent discovery by Anthropic's biolab, comparing its results to CRISPR, is not a present threat to CRISPR Therapeutics; Anthropic's AI is still in its early stages, and gene editing companies like CRISPR already have proprietary technology.
CRISPR Therapeutics' stock could see a significant increase if the company lands a major partnership for its CTX310 drug, which is expected to happen soon given the positive phase 1b data; this would likely dwarf the market's attention to other biotech companies.

Generated by AI

Sentiment

Of the messages about CRSP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	91.25% -4.8	93.42% +3.78	82.59% +2.96
Bearish	0% 0	8.75% +4.8	6.58% -3.78	17.41% -2.96

Bullish· Aug 19

$CRSP has the potential to break out of its long consolidation and make a significant move, with some analysts predicting a price explosion to $85-$115 per share.
The company's gene editing technology, approved by Casgevy, has the potential to revolutionize medicine, making it a leader in the sector and a key player in the future of healthcare.
$CRSP's pipeline is expanding rapidly, with a total addressable market (TAM) of $50B-$100B, making it a prime target for investors looking for a long-term gem in the biotech sector.

Bearish· Jun 4

The stock has been sold by some investors, with one user mentioning a sale at $58 and another warning not to follow Cathy's advice to sell.
The company's valuation is being questioned, with one user suggesting that it is overvalued compared to space companies, and another implying that it is undervalued and forgotten.
The stock's price has been experiencing volatility, with users mentioning a drop below $57, a failed attempt to close above $57, and a potential sell-off in the future.

Generated by AI

Topics

Of the messages about CRSP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	60%	11.54%	22.48%	48.74%
Announcements	40%	13.85%	40.19%	2.02%
Analysts	0%	37.31%	18.86%	48.32%
Earnings	0%	0%	0%	0.02%
Macro	0%	37.31%	18.48%	0.84%
Controversies	0%	0%	0%	0.06%

Earnings· Feb 21

CRISPR Therapeutics AG's Q4 EPS was $1.10, beating the estimate by $1.51.
Sales for Q4 were $201.21M, exceeding the estimate of $131.63M.
The company's revenue topped estimates by $70.98M, with a year-over-year increase of 3253.3%.

Analysts· Dec 11

Analysts have raised their price targets for CRISPR Therapeutics AG (CRSP) to $57-$88, citing the FDA approval of its gene therapy Casvegy.
Needham and Company LLC raised its price target to $88, while JMP Securities raised its target to $80, and Barclays increased its target to $61.
Truist analysts downgraded their price target to $160 from $220, citing scaled-back optimism for Casvegy deployment, while TD Cowen downgraded CRSP to Underperform with a $30 price target.

Announcements· Mar 11

CRISPR Therapeutics AG has priced an upsized convertible senior notes offering of $550M, with a maturity date of March 1, 2031, and an option to purchase an additional $50M.
The offering was upsized from the initially announced $350M, with the proceeds expected to be used for general corporate purposes.
The notes will have an effective coupon of 1.7308%, with interest payable semiannually in arrears, and will be senior, unsecured obligations of the company.

Controversies· Jun 11

CRISPR Therapeutics AG's gene-editing technology may cause cancer, according to two studies, leading to a decline in stock prices for CRSP and similar companies.
The CEO of CRSP, Sam Kulkarni, acknowledged the potential cancer threat, stating that the results of the studies were "plausible".
Gene-editing startups, including CRSP and Editas Medicine, downplayed the potential cancer side effect, with some studies suggesting that the technology may not be as risky as initially thought.

Technical Analysis· Dec 11

$CRSP is holding back testing and down-trend line, with an ideal scenario being an undercut and rally.
$CRSP's pullback after a massive run is considered normal action, following a wave 2 pattern, and is expected to bounce back up.
$CRSP's daily chart is forming a bear flag, and it is expected to see a bounce off the 200-day moving average, potentially at $52 or $53.

Generated by AI

Community

Of the messages about CRSP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	51.35%	32.09%	46.77%	18.91%
Newcomers	48.65%	67.91%	53.23%	81.09%

Regulars· Sep 23

$CRSP's stock price is stuck in a tight range, and regulars are waiting to see when it will break through and what will happen next.
Anthropic's discovery is being compared to CRISPR's, but regulars believe that Anthropic's biotech arm is a long way off, and they will need to build a lot of bench work and context to truly have a functional biotech arm.
The market is delusional about AI's potential to fast-track clinical trials, and regulars believe that CRISPR's stock will continue to be driven by the company's pipeline and potential partnerships, which could send the stock to 100+ in a heartbeat.

Newcomers· Jun 18

New investors are entering the market, as evidenced by the comment "dammit just bought CRSP", indicating a recent purchase of the asset.
Some newcomers are expressing frustration or excitement about their investment, as seen in the comment "dammit", suggesting a strong emotional response to the asset's performance.
The asset is being bought, rather than sold, indicating a bullish sentiment among these newcomers.

Generated by AI

CRISPR Therapeutics

Social

Sep 23

Bullish· Aug 19

Bearish· Jun 4

Earnings· Feb 21

Analysts· Dec 11

Announcements· Mar 11

Controversies· Jun 11

Technical Analysis· Dec 11

Regulars· Sep 23

Newcomers· Jun 18

CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?

CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens

CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality

CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As Book Value Questions Linger

Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP)

Gene editing stocks fall on Anthropic’s CRISPR-like discovery

Also Discussed

CRISPR Therapeutics AG

Company Information

Location

CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?

CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens

CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality

CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As Book Value Questions Linger

Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP)

Gene editing stocks fall on Anthropic’s CRISPR-like discovery

Also Discussed

Social

Sep 23

Bullish· Aug 19

Bearish· Jun 4

Earnings· Feb 21

Analysts· Dec 11

Announcements· Mar 11

Controversies· Jun 11

Technical Analysis· Dec 11

Regulars· Sep 23

Newcomers· Jun 18